NYSE · BFLY
Butterfly Network, Inc.
$7.51-$0.30 (-3.84%)
Butterfly Network, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.44% below the high.
Loading market information…
NASDAQ · RXST · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RxSight, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
RxSight, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow RxSight, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 7, 2025 |
| -$0.20+7.7% vs estimate |
| $37.90M-0.49% vs estimate |
| Q4 2024 | Feb 25, 2025 | -$0.15+9.57% vs estimate | $40.21M-0.24% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.16+36.0% vs estimate | $45.41M+12.49% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $6.38.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.51-$0.30 (-3.84%)
Butterfly Network, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.44% below the high.
$31.52+$0.72 (+2.34%)
OrthoPediatrics Corp.’s quoted price sits in the upper half of its reported 52-week range, 3.37% below the high.
$42.98+$0.15 (+0.35%)
Surmodics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.06% below the high.
$24.31+$0.40 (+1.67%)
Tactile Systems Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.64% below the high.
$9.52-$0.30 (-3.05%)
DiaMedica Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.64% below the high.
$14.64-$0.22 (-1.48%)
Delcath Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.96% below the high.
$2.44+$0.02 (+0.83%)
Cerus Corporation’s quoted price sits in the upper half of its reported 52-week range, 29.68% below the high.
$13.01+$0.08 (+0.62%)
NeuroPace, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.62% below the high.
